Viewing Study NCT00715208


Ignite Creation Date: 2025-12-26 @ 10:57 AM
Ignite Modification Date: 2026-02-05 @ 5:30 PM
Study NCT ID: NCT00715208
Status: COMPLETED
Last Update Posted: 2013-04-29
First Post: 2008-07-11
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Sponsor: Millennium Pharmaceuticals, Inc.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed Follicular Lymphoma View
Keywords: